invIOs presents exciting preclinical data showing that immune-activating small molecule INV501 induces strong cytotoxic activity against solid tumors

invIOs publicly disclosed data for the first time from its high-potential small molecule program, INV501, showing that the novel compound can induce strong anti-tumor immune responses.

INV501 comprises a class of novel small molecules that can selectively enhance tumor-reactive cytotoxicity in preclinical in vivo model systems. The data show that INV501 significantly inhibits tumor growth, resulting in prolonged survival and increased cure rates even beyond the end of treatment when administered as an oral single agent in an orthotopic murine B16-SIY melanoma model.

Similarly, in a breast cancer model using EO771 cells, tumor growth was significantly inhibited and survival prolonged even beyond the end of treatment. INV501 is orally available and has good bioavailability as well as a favorable pharmacokinetic profile.

Read more